Generalized epilepsy with febrile seizures-plus

Get in touch with RARE Concierge.

Contact RARE Concierge

Synonyms: GEFS+ | Genetic epilepsy with febrile seizures-plus

Generalized epilepsy with febrile seizures plus (GEFS+) is a familial epilepsy syndrome in which family members display a seizure disorder from the GEFS+ spectrum which ranges from simple febrile seizures (FS) to the more severe phenotype of myoclonic-astatic epilepsy (MAE) or Dravet syndrome (DS) (see these terms).

Data from Orphanet are used to provide information on a disease's name, synonym(s), and overview. Reference: Access aggregated data from Orphanet at Orphadata. Orphadata: Free access data from Orphanet. © INSERM 1999. Available on http://www.orphadata.org. Data version June 2024

Newly diagnosed with
Generalized epilepsy with febrile seizures-plus?

Our RARE Concierge Services Guides are available to assist you by providing information, resources and connections as you navigate your rare disease journey.

Get Concierge Help

Advocacy Organizations

Cure GABA-A Variants

Our vision at Cure GABA-A is a future where individuals living with GABA-A Variants experience improved quality of life and have access to personalized treatments. We envision a world where repurposed FDA-approved drugs and gene therapies offer hope and relief to patients, effectively managing symptoms and addressing the underlying genetic causes of GABA-A Variants. Our organization has the sole focus of understanding the most efficient and effective way to develop potential therapies for GABA-A Variants.

Pediatric Epilepsy Research Consortium

The Pediatric Epilepsy Research Consortium (PERC) is a group of US pediatric epilepsy centers, researchers and professionals in field of epilepsy whose goal is to provide a network and infrastructure to facilitate collegial, collaborative practice-changing research that will provide answers needed to improve the care of children with epilepsy.

Don't see your organization here. Let us know here.

Clinical Trials

For a list of clinical trials in this disease area, please click here.